MacuHealth News
MacuHealth Announces its Support of ASCO
MacuHealth, an innovator in the field of ocular supplements, is honored to support with the Association of Schools and Colleges of Optometry and its mission to advance optometric education and research to enhance the public's health and well-being.
After witnessing his mother's sight deteriorate due to age-related macular degeneration, entrepreneur Frederic Jouhet sought a safe, effective supplement that managed the disease's debilitating symptoms. In 2006, he founded MacuHealth, whose mission is to set a new standard for nutritional supplements in the eye care industry.
“We are committed to science, innovation and providing the utmost quality to our customers,” Jouhet said.
Over 30 peer-reviewed studies support that MacuHealth's Triple Carotenoid Formula, consisting of 10 mg of Lutein, 10 mg of Meso-Zeaxanthin and 2 mg of Zeaxanthin, rebuilds the density of the macular pigment. Our formulation is clinically proven to manage AMD symptoms and maintain eye health, including improved contrast sensitivity, reaction time and enhanced filtration from harmful blue light.
Our dedication to research is why optometrists and other eye care professionals worldwide have aligned with MacuHealth, helping to make us leaders in the premium macular supplement market. And we've expanded our products offerings to include MacuHealth Plus+, based on the AREDS2 formula, and Vizion Edge ECP, clinically proven to boost the visual performance of athletes so they can reach their peak.
In 2021, we furthered our commitment to eye health with our fish oil formula TG Omega-3, shown to manage symptoms of dry eye as well as unparalleled benefits to the heart, brain and immune system. We look forward to sharing our plans for 2022 with ASCO's members.
"Our quest has always been to embrace the science and provide the best solutions to eye care professionals and patients," Jouhet said. "Investing in education is part of that journey, and our partnership with ASCO will ensure it will continue well into the future."